Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.54 |
| ▸ | DGAT1 | O75907 | 9/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939728 | 0.89 | DGAT1 (0.56) | DGAT1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL180693 | 0.88 | MAPT (0.60) | DGAT1CFTRMEN1POLBMAPT | |
| SCHEMBL14617023 | 0.86 | MEN1 (0.61) | CYP1A1CYP1A2CYP1B1DGAT1MEN1 | |
| SCHEMBL180967 | 0.86 | DGAT1 (0.51) | DGAT1CFTRMEN1NPC1ALDH1A1 | |
| SCHEMBL180959 | 0.86 | MEN1 (0.61) | CYP1A1CYP1A2CYP1B1DGAT1MEN1 | |
| SCHEMBL13664061 | 0.86 | MEN1 (0.61) | CYP1A1CYP1A2CYP1B1DGAT1MEN1 | |
| SCHEMBL4494798 | 0.84 | ALOX5 (0.57) | CYP1A1CYP1A2CYP1B1DGAT1ALOX5 | |
| SCHEMBL15062884 | 0.84 | DGAT1 (0.59) | DGAT1 | |
| SCHEMBL4942376 | 0.83 | DGAT1 (0.53) | DGAT1NPY5RMEN1NPC1RAB9A | |
| SCHEMBL4939205 | 0.83 | ALOX5 (0.56) | CYP1A1CYP1A2CYP1B1DGAT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | claimed |
| CN-101415683-B | Novel compounds | NOVARTIS AG | 2013-07-17 | — | — | CN | claimed |
| CN-103086981-A | New compounds | NOVARTIS AG | 2013-05-08 | — | — | CN | claimed |
| US-20130018054-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | claimed |
| EP-2418202-A1 | New compounds | Novartis AG (CH) | 2012-02-15 | — | — | EP | claimed |
| EP-2402320-A1 | Anorectic agents | Novartis AG (CH) | 2012-01-04 | — | — | EP | claimed |
| EP-2301923-A1 | New compounds | Novartis AG (CH) | 2011-03-30 | — | — | EP | claimed |
| US-20090247534-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2009-10-01 | — | — | US | claimed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | claimed |
| CN-101415683-A | Novel compounds | NOVARTIS AG (CH) | 2009-04-22 | — | — | CN | claimed |
| EP-2004607-A2 | NEW COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | claimed |
| CN-103288721-B | (4-(4-[6-(trifluoromethylpyridin-3-base amino)-containing N heteroaryl]-phenyl)-cyclohexyl)-acetogenin and pharmaceutical use thereof | NOVARTIS AG (CH) | 2016-04-20 | — | — | CN | disclosed |
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912208-B2 | (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity | NOVARTIS AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8835451-B2 | Compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| CN-101415683-A | Novel compounds | NOVARTIS AG (CH) | 2009-04-22 | — | — | CN | disclosed |
| EP-2004607-A2 | NEW COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008073865-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | CYP1A1 1824/4885CYP1A2 1814/4885CYP1B1 1238/4885 |
| US-20090247534-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | CYP1A1 1824/4885CYP1A2 1814/4885CYP1B1 1238/4885 |
| US-20130018054-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | CYP1A1 1780/4885CYP1A2 1773/4885CYP1B1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.